Clinical Trials Logo

Prostatic Diseases clinical trials

View clinical trials related to Prostatic Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05941260 Completed - Clinical trials for Prostate Hyperplasia

Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics

Start date: July 15, 2023
Phase:
Study type: Observational

The enlargement of the prostate is responsible for voiding dysfunction in men, and especially elderly men. The primary surgical treatment for symptomatic benign prostatic hypertrophy (BPH) was transurethral resection of the prostate (TURP). However, current resection techniques are predominantly experience-based and judgment-based, with little evidence to support the most effective portion of the prostate to be respected. So, the investigators plan through the study to construct a flow diagram to evaluate the amount of tissue needed to be resected to improve voiding flow dynamics.

NCT ID: NCT05834270 Completed - Prostatic Neoplasms Clinical Trials

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

NCT ID: NCT05803096 Completed - Prostate Cancer Clinical Trials

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

Start date: December 12, 2021
Phase: Phase 4
Study type: Interventional

Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient's anxiety and pain. This study seeks to determine whether administration of nitrous oxide at the time of prostate biopsy will improve a patient's experience of care.

NCT ID: NCT05399940 Completed - Prostate Cancer Clinical Trials

The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

Purpose: To find the correlation between hemogram parameters and Delta Neutrophil Index(DNI) and Serum PSA in patients presenting with the diagnosis of acute prostatitis. Material-Metod: Serum PSA levels and hemogram parameters of patients who came to the urology outpatient clinic in January 2018 and May 2022 and were diagnosed with prostatitis were collected retrospectively.

NCT ID: NCT03192917 Completed - Clinical trials for Erectile Dysfunction

Low-energy Extracorporeal Shockwave Treatment for Patients After Radical Prostatectomy

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this project is to verify the relationship between low intensity shock wave treatment (LI-SWT) and increased scores in self-assessment regarding to erectile function (ED) and sexual intercourse, in patients, who has undergone a radical prostatectomy (RP). The data will be obtained from patients using international accepted sexual questionnaires prior to the LI-SWT and 5, 12 and 24 weeks following treatment.

NCT ID: NCT03104907 Completed - Clinical trials for Lower Urinary Tract Symptoms

Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer including pelvic pain, bleeding or need for permanent urinary catheter who are unfit for or refuse surgical treatment.

NCT ID: NCT03099421 Completed - Clinical trials for Lower Urinary Tract Symptoms

Prostatic Artery Embolization for Benign Prostatic Obstruction

Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization (PAE) for patients who refuse or are not eligible for surgery with moderate-severe lower urinary tract symptoms or indwelling catheter secondary to benign prostate obstruction due to benign prostatic hyperplasia.

NCT ID: NCT02074644 Completed - Clinical trials for Lower Urinary Tract Symptoms

Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia

Start date: September 2, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether prostatic arterial embolization (PAE) compared is an effective and safe treatment for benign prostatic hyperplasia in patients with severe lower urinary tract symptoms not adequately controlled by medical therapy with alpha-blockers, as assessed by the the International Prostate Symptom Score (IPSS) after 6 months. Patients will be randomized on a 1:1 ratio to PAE or to a sham procedure and evaluated at 1, 3 and 6 months. Patients randomized to the sham procedure will be offered the possibility of performing PAE after 6 months. All patients may participate on an optional 6-months extension study.

NCT ID: NCT01826617 Completed - Prostate Cancer Clinical Trials

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome

Start date: December 2010
Phase: N/A
Study type: Observational [Patient Registry]

This study will identify significant clinical parameters and individual risk factors related to certain prostate disease (BPH, prostatitis and prostate cancer). With the identified important correlations, a locally generated bias free nomogram will be constructed for predicting prostate biopsy outcome among Asian men with indications for prostate biopsy. While this study will evaluate the accuracy and predictive value of this novel prostate disease nomogram.

NCT ID: NCT01316458 Completed - Prostatic Neoplasm Clinical Trials

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Start date: June 2003
Phase: Phase 2
Study type: Interventional

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.